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ARTICLE
Cotransporter-mediated water transport underlying
cerebrospinal ﬂuid formation
Annette B. Steffensen1, Eva K. Oernbo1, Anca Stoica1, Niklas J. Gerkau2, Dagne Barbuskaite3, Katerina Tritsaris3,
Christine R. Rose 2 & Nanna MacAulay 1
Cerebrospinal ﬂuid (CSF) production occurs at a rate of 500ml per day in the adult human.
Conventional osmotic forces do not sufﬁce to support such production rate and the molecular
mechanisms underlying this ﬂuid production remain elusive. Using ex vivo choroid plexus live
imaging and isotope ﬂux in combination with in vivo CSF production determination in mice,
we identify a key component in the CSF production machinery. The Na+/K+/2Cl− cotran-
sporter (NKCC1) expressed in the luminal membrane of choroid plexus contributes
approximately half of the CSF production, via its unusual outward transport direction and its
unique ability to directly couple water transport to ion translocation. We thereby establish the
concept of cotransport of water as a missing link in the search for molecular pathways
sustaining CSF production and redeﬁne the current model of this pivotal physiological pro-
cess. Our results provide a rational pharmacological target for pathologies involving disturbed
brain ﬂuid dynamics.
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The mammalian brain is bathed in the cerebrospinal ﬂuid(CSF), which is continuously produced at a rate ofapproximately 500 ml ﬂuid per day in the adult human1.
Prior to exiting the brain, the CSF travels through the ventricular
system and part of it re-enters the brain via the para-vascular
route along the large arteries and penetrating arterioles2,3. The
CSF is predominantly produced by the choroid plexus, an epi-
thelial monolayer resting on highly vascularized connective tissue
and located at the base of each of the four ventricles4–7. The
molecular mechanisms underlying this choroidal ﬂuid production
remain unresolved. Dysregulation of CSF production or clearance
may lead to brain water accumulation and raised intracranial
pressure, as evident in patients with hydrocephalus. Hydro-
cephalus most commonly occurs as a consequence of obstructed
CSF outﬂow, and is routinely treated by insertion of a ventriculo-
peritoneal shunt diverting the excessive ﬂuid from the ventricles
into the peritoneal cavity in the abdomen8. However, in certain
choroidal pathologies, such as choroid plexus hyperplasia, chor-
oid plexus papilloma, and posthemorrhagic hydrocephalus, the
increased intracranial pressure occurs, at least in part, from CSF
overproduction6,9,10. The molecular mechanisms underlying the
pathologic increase in CSF production remain elusive. Insight
into the transport mechanisms underlying brain CSF accumula-
tion could provide a rational therapeutic target to reduce this
pathologic brain ﬂuid accumulation.
The CSF production is generally assumed to take place by
transport of osmotically active ions (e.g. sodium by the Na+/K
+-ATPase11,12) followed by osmotically obliged, passive movement
of water, partly via the water channel aquaporin 1 (AQP1)
expressed at the luminal membrane of the choroid plexus13,14.
However, several observations suggest that such a simple osmotic
model may not be adequate: (1) The CSF production declined by a
mere 20% in the AQP1 knock-out mice, partly ascribed to the 80%
reduction of central venous blood pressure in these mice15. (2) With
the known osmotic water permeability across the choroid plexus,
detailed calculations have demonstrated that the osmolarity of the
CSF must exceed that of the plasma by as much as 250mOsm (in
contrast to the measured difference in osmolarity of 5−10
mOsm16,17) in order for the CSF to be produced at the observed
rate by simple osmosis18. (3) The choroid plexus has the ability to
produce CSF against an oppositely directed osmotic gradient18–21.
Taken together, conventional aquaporin-mediated osmotic water
transport does not sufﬁce to sustain the rates of CSF production
consistently observed in mammals.
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Fig. 1 Cotransporter-mediated active water transport against an osmotic gradient. a Image of calcein ﬂuorescence in mouse choroid plexus (CP, top) and
the converted image (bottom) with indication of the region of interest (red box). Scale bar= 60 µm. b Volume changes of CPs challenged with a 100
mOsm gradient of mannitol (M), indicated by the extended bars (n= 5 CPs from ﬁve mice). c CPs challenged with a 100mOsm gradient of ﬁrst mannitol
(M), then NaCl, and ﬁnally mannitol, indicated by the extended bars (n= 6 CPs from six mice). d CPs challenged with a 100mOsm gradient of ﬁrst
mannitol (M), then KCl, and ﬁnally mannitol, indicated by the extended bars (n= 6 CPs from six mice). e Summary of the second volume change induced
by identical osmotic gradients. f CPs challenged with 100mOsm KCl alone (control, black symbols, data from d) or in the presence of 1 mM furosemide
(purple symbols, n= 6 CPs from six mice). Inset magniﬁes the area of interest where furosemide blocks the KCl-induced swelling. g CPs challenged with
100mOsm alone (control, black symbols, data from d) or in the presence of 10 µM bumetanide (blue symbols, n= 6 CPs from six mice). Inset magniﬁes
the area of interest where bumetanide blocks the KCl-induced swelling. h CPs challenged with 100mOsm KCl (control, black symbols, data from d) and in
the absence of Na+ in the test solution (green symbols, n= 4 CPs from four mice). Inset magniﬁes the area of interest where lack of Na+ blocks the KCl-
induced swelling. i Summary of the second volume change induced by KCl alone or with drug application/Na+ omission. Error bars represent standard
error of the mean and statistical signiﬁcance was tested with one-way ANOVA followed by Tukey’s multiple comparisons test. In panel e, the asterisks
refer to a comparison to the mannitol-mediated shrinkage and in panel i, the asterisks refer to a comparison to the KCl-mediated swelling. **P < 0.01,
***P < 0.001, NS not signiﬁcant
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A number of cotransporter proteins have the inherent ability to
cotransport water along with the ions/solutes in the translocation
mechanism (for review see refs. 18,22). The coupling between
water translocation and substrate transport takes place within the
protein itself in a manner that permits water to be transported
independently of, and even against, an osmotic gradient23.
Examples of such water-translocating cotransporters are the Na
+/K+/2Cl− cotransporter 1 (NKCC1) and the K+/Cl− cotran-
sporters (KCCs)24–26. Isoforms of these transport proteins have
been detected in the choroid plexus epithelium27–29, although
their exact isoform distribution, relative expression, and mem-
brane targeting remain largely unknown, as are their ability to
transport water independently of an osmotic gradient in the
choroid plexus tissue and their contribution to CSF production
in vivo. In the present study, we introduce the water-translocating
cotransporter, NKCC1, as the main contributor to CSF formation
in the mouse choroid plexus.
Results
Choroidal cotransport of water against an osmotic gradient. To
determine if membrane transport mechanisms in the luminal
membrane of choroid plexus carry an inherent ability to trans-
locate water against an osmotic gradient, ex vivo mouse choroid
plexus was monitored by live imaging during exposure to osmotic
challenges. The acutely isolated choroid plexus was loaded with
calcein-AM and the water movement determined as two-
dimensional volume changes occurring as movement of the
choroid plexus upon exposure to a hyperosmotic challenge of
100 mOsm (Fig. 1a). Three consecutive applications of 100 mOsm
(100 mM) mannitol led to robust and reproducible shrinkage of
choroid plexus (n= 5, Fig. 1b). This pattern was replicated with
NaCl as the osmolyte (100 mOsm, 55 mM) during the second
application (n= 6, Fig. 1c) while keeping mannitol application as
a reference for the ﬁrst and last osmotic challenge. In contrast,
application of a 100 mOsm hyperosmolar challenge introduced
via addition of KCl (55 mM) generated an abrupt choroid plexus
volume increase (n= 6, Fig. 1d), indicating that water was
transported into the choroid plexus despite the large oppositely
directed osmotic gradient. It should be noted that the volume
increase occurred instantaneously prior to signiﬁcant changes in
intracellular parameters22,25. Summarized data from the second
osmolyte application illustrate that the volume decrease obtained
upon application of 100 mOsm mannitol (12.7 ± 2.2%, n = 5) or
NaCl (11.3 ± 3.1%, n = 6) P= 0.96, df= 14, q= 0.4) reached
comparable levels (Fig. 1e), while application of an identical
osmotic challenge given in the form of KCl produced a volume
increase of 12.4 ± 4.5%, n = 6 (one-way ANOVA followed by
Tukey’s multiple comparisons test, P= 0.0006, df= 14, q= 6.9,
Fig. 1e). These results indicate that choroid plexus contains
transport mechanisms capable of transporting water indepen-
dently of, and even against, the direction of an applied osmotic
gradient. To determine the involvement of cation-chloride
cotransporters (CCCs) in the K+-mediated transport of water
against an experimentally applied osmotic gradient, we continued
the experimental series described above with the inclusion of
pharmacological agents. Application of furosemide (1mM inhibits
both KCCs and NKCCs30) completely blocked the K+-mediated
choroid plexus volume increase: The tissue responded in a passive
manner, as when challenged with mannitol as the osmolyte
(shrinkage of 5.7 ± 1.3%, one-way ANOVA followed by Tukey’s
multiple comparisons test, P= 0.0006, df= 18, q= 6.9, n= 6,
Fig. 1f). For illustrative purposes, the volume traces obtained in
control solution in the previous ﬁgure (Fig. 1d) are included in
black. Inclusion of bumetanide (10 µM inhibits NKCC131, 8.6 ±
1.7% shrinkage, one-way ANOVA followed by Tukey’s multiple
comparisons test, P= 0.0001, df= 18, q= 8.0, n= 6, Fig. 1g) or
removal of Na+ from the test solution (equiosmolar replacement
with choline; 4.5 ± 0.5% shrinkage, one-way ANOVA followed by
Tukey’s multiple comparisons test, P= 0.0037, df= 18, q= 5.8, n
= 4, Fig. 1h) likewise abolished the K+-mediated water accumu-
lation. Data are summarized in Fig. 1i. Increased [K+]e thus
promoted inwardly directed ion transport by NKCC1, which by
its ability to cotransport water during its translocation
mechanism contributed to intracellular water accumulation
against a substantial osmotic gradient. Cotransporter-mediated
water transport is thereby indeed able to move water across the
choroid plexus membrane in a manner independent of an
osmotic gradient.
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Fig. 2 NKCC1 and KCC1 are expressed in mouse choroid plexus. a mRNA expression levels of NKCC1 and the four KCC isoforms in mouse choroid
plexuses. The ﬁve target genes were normalized to two reference genes, GAPDH and H2AFZT, and presented as relative expression; NKCC1= 60.0 ± 3.9,
KCC1= 21.2 ± 1.8, KCC2= 0.2 ± 0.1, KCC3= 1.2 ± 0.1, and KCC4= 3.2 ± 0.2 (n= 6 mice), error bars represent standard error of the mean. b
Representative western blots to verify antibody speciﬁcity. NKCC1 and KCC1-4 were expressed in Xenopus laevis oocytes and puriﬁed membranes from
these and uninjected oocytes were exposed to SDS-PAGE followed by western blot (n= 3 experiments). c−fWestern blots of lysates from mouse choroid
plexus demonstrated expression of NKCC1 (c) and KCC1 (d), while KCC2 (e) and KCC4 (f) were not detected. Beta-tubulin was employed as loading
control (n= 3 experiments)
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NKCC1 and KCC1 are expressed in choroid plexus. To deter-
mine the isoform-speciﬁc expression proﬁle of NKCC1 and the
KCCs in mouse choroid plexus, we initially performed quanti-
tative PCR on mRNA puriﬁed from acutely isolated tissue.
Normalization of the obtained quantities of mRNA encoding
NKCC1 and KCC1-4 to two reference genes illustrated a robust
expression of NKCC1 and, although to a lesser extent, KCC1,
while KCC2-4 mRNA expression was minor or below detection
limit (n= 6, Fig. 2a). Prior to determination of the protein
expression of the CCCs in choroid plexus tissue, we veriﬁed that
the employed antibodies exclusively recognized their targeted
isoform. To this end, NKCC1 and KCC1-4 were individually
expressed in Xenopus laevis oocytes and puriﬁed membranes
containing each isoform were exposed to SDS-PAGE followed by
western blot with antibodies targeting each of these transport
proteins. As evident from Fig. 2b, the employed antibodies
recognized only their respective target protein with no isoform
cross-reaction (n= 3). We were, however, unsuccessful with all
ﬁve KCC3 antibodies tested, none of which properly recognized
KCC3, either due to poor epitope recognition or lack of KCC3
expression in the oocytes. Western blotting of lysates from mouse
choroid plexus demonstrated robust immunoreaction with anti-
bodies targeting NKCC1 and KCC1, while KCC2 and KCC4 were
below detection limit in this tissue (n= 3, Fig. 2c, f). None of the
ﬁve tested KCC3 antibodies provided indications of immunor-
eactivity in the choroid plexus tissue, indicating either lack of
choroidal expression of this isoform or poor epitope recognition.
Taken together, mRNA and protein analysis illustrate robust
expression of NKCC1 and KCC1 in the mouse choroid plexus
and negligible expression of KCC2-4.
NKCC1 is localized to the luminal membrane in choroid
plexus. Localization of NKCC1 and KCC1 to the luminal mem-
brane of the choroid plexus is required in order for these to
directly transport water into the ventricular lumen. Immunohis-
tochemical staining of mouse choroid plexus veriﬁed the locali-
zation of NKCC1 at the luminal membrane (green, Fig. 3a). Three
antibodies directed towards KCC1 produced only diffusive, and
therefore inconclusive, staining in choroid plexus tissue. To
determine the membrane targeting of KCC1 in an alternative
fashion, we performed surface biotinylation of the choroid plexus.
Rupture of the choroidal tissue during the isolation procedure
yielded undesirable access of the biotin to the basolateral mem-
brane. Instead, selective biotinylation of the lumen-facing chor-
oidal membrane was obtained by ventricular delivery of biotin in
the intact animal, prior to isolation of the choroid plexus and
puriﬁcation of the biotinylated proteins (see Fig. 3b for a diagram
of the procedure). Densitometric analysis of the western blots of
the biotinylated membrane protein fraction relative to the total
membrane protein fraction illustrated NKCC1 enrichment in the
biotinylated (luminal) membrane fraction (Fl) compared to the
total membrane fraction (Ft) (Fig. 3c, left panels, Fl/Ft= 3.2 ± 0.2,
n= 4, one-sample t test and comparison to equal distribution; Fl/
Ft= 1, P= 0.001, t= 11.82, df= 3). In contrast, abundance of
KCC1 was signiﬁcantly lower in the biotinylated fraction (Fig. 3c,
middle panels, Fl/Ft= 0.3 ± 0.0, n= 4, one-sample t test and
comparison to equal distribution; Fl/Ft= 1, P < 0.001, t= 20.1, df
= 3) and resembled the pattern obtained with E-cadherin, a
basolaterally located membrane protein32 (Fig. 3c, right panels,
Fl/Ft= 0.4 ± 0.1, n= 4, one-sample t test and comparison to equal
distribution; Fl/Ft= 1, P= 0.009, t= 6, df= 3). Therefore,
NKCC1, not KCC1, is localized to the luminal membrane of
choroid plexus, from which it could indeed participate in CSF
production.
NKCC1 is poised for outwardly directed transport. The NKCC1
transport is inwardly directed in most cell types33 while pro-
duction of CSF necessitates outwardly directed transport of ions
and water. To reveal the choroidal NKCC1 transport direction,
we determined the ion concentrations of Na+, K+, and Cl− in
choroid plexus epithelial cells and CSF of mice. CSF was extracted
from anesthetized and artiﬁcially ventilated mice by a glass
capillary inserted in cisterna magna. Immediately thereafter, each
mouse was sacriﬁced, choroid plexus isolated (n= 4), and the ion
concentrations determined with ﬂame photometry (Na+ and K+)
or by colorimetry (Cl−). The obtained ion concentrations (CSF:
150 ± 1 mM Na+, 3 ± 0 mM K+, 100 ± 6 mM Cl− and in the
choroid plexus epithelial cells: 31 ± 5 mM Na+, 141 ± 12mM K+,
and 35 ± 9 mM Cl−, n= 4) illustrate that the intracellular Na+
and Cl− concentrations are substantially higher than the 5−15
mM range usually observed in most mammalian cells34. Calcu-
lation of the Gibbs free energy using the obtained ion
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Fig. 3 NKCC1 is located at the luminal membrane facing the ventricles. a Immunostaining of mouse choroid plexus illustrated expression of NKCC1 in the
membrane facing the lumen (green) with E-cadherin (red) as a basolateral marker and nuclei in blue. Scale bar= 10 µm. Previously unpublished image
generously provided by Dr. Jeppe Praetorius. b Schematic illustration of the luminal surface biotinylation of mouse choroid plexus in situ. c Representative
western blots showing expression of NKCC1, KCC1, and E-cadherin in total tissue fraction (Ft) and puriﬁed biotinylated (luminal) membrane protein
fraction (Fl). Below is depicted the quantiﬁcation of protein abundance represented as luminal membrane/total protein fraction (n= 4 mice). NKCC1 was
expressed signiﬁcantly higher in the puriﬁed luminal membrane fraction while KCC1 and E-cadherin were predominantly in the total fraction. Error bars
represent standard error of the mean and statistical signiﬁcance was determined with one-sample t test and comparison to equal distribution; Fl/Ft= 1 and
the asterisks refer to a value signiﬁcantly different from 1. **P < 0.01, ***P≤ 0.001
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concentrations (see Methods) yields ΔG= 448 J mol−1, which
indicates an outwardly directed transport of NKCC1 in the
lumen-facing membrane of mouse choroid plexus epithelial cells
under physiological conditions. To experimentally determine the
transport direction of NKCC1 in choroid plexus epithelial cells,
we performed wide-ﬁeld Na+ imaging on ex vivo choroid plexus,
loaded with SBFI-AM (sodium-binding benzofuran isophthalate
acetoxymethyl ester) (Fig. 4a). In choroid plexus kept in control
aCSF, [Na+]i was stable and did not undergo detectable ﬂuc-
tuations (Fig. 4b). Upon inhibition of NKCC1 (10 μM bumeta-
nide), however, the SBFI ﬂuorescence ratio increased by 8.5 ±
1.2% within 10 min (n= 10, Fig. 4b, c), revealing an increase in
[Na+]i. This increase indicates outwardly directed NKCC1-
mediated Na+ transport. Upon 20 min washout of bumetanide,
the [Na+]i returned towards baseline (2.4 ± 0.6%, n= 5, Fig. 4b),
reﬂecting re-establishment of Na+ export by the NKCC1.
Bumetanide did not compromise cell viability (conﬁrmed by
uptake of calcein-AM as a marker of cell health35, Fig. 4d, n= 4
of each condition), indicating that the observed increase in [Na+]i
did not result from unspeciﬁc inﬂux of Na+, but was indeed due
to blocking of NKCC1 transport activity. The unique transport
direction of NKCC1 was veriﬁed with efﬂux experiments with
86Rb+, a congener for K+, from pre-loaded ex vivo choroid
plexus. The 86Rb+ efﬂux decreased approximately 85% after
exposure to either bumetanide (20 μM, n= 5, one-way ANOVA
followed by Tukey’s multiple comparisons, P < 0.0001, df= 14,
q= 17.6) or furosemide (1 mM, n= 5, one-way ANOVA fol-
lowed by Tukey’s multiple comparisons, P < 0.0001, df= 14, q=
19.3) (Fig. 4e, f), indicating that the K+ efﬂux was predominantly
orchestrated by NKCC1. Together, these results show that the ion
concentrations of choroid plexus epithelial cells uniquely dictate
outwardly directed transport of NKCC1, which thus could act as
a contributor to CSF production.
NKCC1 signiﬁcantly contributes to CSF production in vivo. To
determine the contribution of NKCC1 to CSF production in vivo,
we performed experiments on anesthetized mice placed in a
stereotaxic frame during ventriculo-cisternal perfusion (modiﬁed
from refs. 15,36). In this experimental approach, aCSF containing
ﬂuorescent dye (dextran) is perfused via a cannula through the
lateral ventricle of the mouse (0.7 µl min−1) with simultaneous
ﬂuid collection by a glass capillary from the cisterna magna at 5-
min intervals (Fig. 5a). The dilution of the ﬂuorescent dye
represents the rate of CSF production. As our experimental
protocol was based on employing each mouse as its own control,
it was an absolute requirement to record a sustained rate of CSF
production throughout the prolonged experimental procedure
(125 min). To obtain such standard, the animals were artiﬁcially
ventilated, their heart rate, respiratory partial pressure of carbon
dioxide, and arterial oxygen saturation were monitored, and their
core temperature maintained (see Methods). A representative
time control experiment is depicted in Fig. 5b, in which the
dextran gradually appeared in the CSF samples and a stable
dilution obtained after approximately 40 min. The last two sam-
ples prior to the solution change (60 min, marked in red in
Fig. 5b) were employed to calculate the CSF production rate of
0.66 ± 0.02 µl min−1 (n= 18, Fig. 5b inset). A similar CSF pro-
duction rate (0.60 ± 0.02 µl min−1, n= 6, P= 0.21, t= 1.3, df=
22, t test) was obtained in a set of animals anesthetized with
isoﬂurane rather than ketamine/xylazine (see Methods). The
vehicle (DMSO)-containing aCSF delivered to the lateral ventricle
was replaced with new DMSO-containing aCSF at the time point
marked “solution change”. After 60 min additional sample time,
the last two sample points (blue in Fig. 5b) were normalized to
the original baseline (the red points) revealing a slight (although
non-signiﬁcant) drop of baseline to 92.2 ± 3.3% during the course
of the experiment (n= 6, one-way ANOVA followed by Tukey’s
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multiple comparisons, P= 0.06, t= 2.4, df= 5, Fig. 5c), demon-
strating rather stable CSF production throughout the experi-
mental procedure. To determine the quantitative contribution of
NKCC1 to CSF production, aCSF including bumetanide (100
µM) was introduced with the solution change, which reduced the
CSF production to 51.0 ± 3.5% of baseline (n= 6, one-way
ANOVA followed by Tukey’s multiple comparisons, P < 0.0001,
df= 15, q= 13.9, Fig. 5c). Inclusion of the NKCC1/KCC inhi-
bitor furosemide (2 mM) reduced the CSF production to 38.8 ±
1.8% of baseline (n= 6, one-way ANOVA followed by Tukey’s
multiple comparisons, P < 0.0001, df= 15, q= 18.0, Fig. 5c),
slightly more than that observed with bumetanide (one-way
ANOVA followed by Tukey’s multiple comparisons, P= 0.03, df
= 15, q= 4.1). Based on these results, it is evident that NKCC1 is
a substantial contributor to the molecular machinery underlying
CSF production in an in vivo experimental setting. While this
dilution method reﬂects CSF production of all origins (all four
choroid plexuses in addition to trans-capillary ﬂuid production),
delivery of a pharmacologic inhibitor via the cannula placed in
one lateral ventricle may not reach the transport mechanisms
expressed in the choroid plexus at the base of the contralateral
ventricle. To obtain an estimate of the reach of such one-sided
drug delivery, Evans blue was infused into one lateral ventricle in
a manner mimicking the experimental approach above, prior to
isolation of the brain. As evident in Fig. 5d, staining was
predominantly observed in the perfused lateral ventricle with
little staining in the contralateral one. We therefore predict partial
inhibition of the cotransporters in the contralateral choroid
plexus and that our data thus represent an underestimate of the
role of NKCC1 in CSF production.
Live imaging shows NKCC1-mediated CSF production. To
obtain a swift and less-invasive manner of revealing NKCC1-
mediated CSF production, we developed an in vivo imaging
strategy based on the LI-COR Pearl Trilogy small animal imaging
system. This method allows imaging of anesthetized animals
immediately after lateral ventricular delivery of a ﬂuorescent dye
(IRDye 800CW carboxylate). The ventricular dye redistribution is
employed as a proxy of CSF production, although diffusion of the
dye is expected to contribute to its redistribution. Figure 6a
illustrates the head of a white mouse (obtained as a white light
image) immediately after ventricular delivery of the ﬂuorescent
probe (superimposing of pseudo-color ﬂuorescence). The red
square indicates the area of interest, in which the dye intensity is
determined as a function of time (representing movement of
CSF) (Fig. 6b, d). After 5-min pre-injection of inhibitor (or
vehicle) the ﬂuorescent dye was injected into one lateral ventricle
along with inhibitor (or vehicle)-injection, and the mouse rapidly
placed in the LI-COR Pearl (exactly 1 min lapse from injection to
ﬁrst image acquisition); see Fig. 6d for representative images. The
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ﬂuorescence intensity recorded in the area of interest was nor-
malized to the intensity of the ﬁrst image, summarized, and illu-
strated as a function of time (Fig. 6b). Inclusion of bumetanide
(100 μM, n= 8, two-way analysis of variance (ANOVA) (repeated
measures (RM)) followed by Tukey’s multiple comparisons test, P
= 0.0018, df= 399, q= 4.9) or furosemide (2mM, n= 6, two-way
ANOVA (RM) followed by Tukey’s multiple comparisons test, P
= 0.0083, df= 399, q= 4.2) signiﬁcantly decreased the movement
of dye compared to control, indicative of NKCC1-mediated
movement of ventricular ﬂuorescence and thus CSF ﬂow. Of note,
injection of Evans blue, in a manner and quantity mimicking the
experimental approach above, predominantly stained the ipsi-
lateral ventricle (Fig. 6c), indicative of a putative underestimation
of the inhibitor-sensitive movement of the ﬂuorescent dye.
Discussion
Here, we have demonstrated, by complementary ex vivo and
in vivo experimentation, that the high production rate of CSF is
sustained by NKCC1 via its inherent ability to cotransport water
along with its directional ion translocation in a manner inde-
pendent of osmotic driving forces. This unconventional means of
ﬂuid secretion underlying CSF production represents a paradigm
shift in the ﬁeld and provides a long-needed rational therapeutic
target towards brain pathologies involving disturbances in brain
water homeostasis and increased intracranial pressure.
The limitations of a conventional osmotic model for CSF
production are apparent from three independent lines of evi-
dence: The minimal effects of genetic deletion of AQP1, the low
osmotic water permeability of the epithelium, and the ability of
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the choroid plexus epithelium to transport water uphill against a
transepithelial osmotic gradient. Firstly, discovery of AQP1 in the
lumen-facing membrane of choroid plexus initially promoted its
implication in CSF production13,15,27. A slightly reduced CSF
production was observed in AQP1−/− mice, although accom-
panied by a severe drop in venous blood pressure in these ani-
mals15. With the general view that CSF originates from the
vascular compartment37,38, taken together with a ﬁvefold higher
arterial ﬂow in choroid plexus compared to that of the brain as a
whole12, such AQP1-dependent reduction in blood pressure15 is
anticipated to contribute to the reduced CSF production observed
in AQP1−/− mice. Secondly, it has been assumed that CSF pro-
duction takes place via conventional osmotic water transport
following a ventricular build-up of osmotic particles
through activity of choroidal membrane transport mechanisms,
such as the Na+/K+-ATPase, cotransporters, and/or ion
channels1,4,13. Concerted action of these transport mechanisms
renders the CSF approximately 5−10 mOsm hyperosmolar
relative to plasma16,17. With the established water permeability
of the choroid plexus epithelium39, calculations dictate that the
transepithelial osmotic gradient entailed to sustain the high
CSF production rate would need to be about 50 times greater
than that observed18. Thirdly, while the rate of CSF production
indeed increases with raised ventricular osmolarity, CSF pro-
duction continues even when the ventricular ﬂuid is hypos-
motic to plasma18–21. In goat, the in vivo CSF production
continued despite opposing osmotic gradients of up to 100
mOsm20.
Simple osmotically obliged water entry into the ventricle is
therefore insufﬁcient to sustain the well-established rate of CSF
production and here we propose cotransport of water as the
molecular mechanism underlying CSF production. Our research
group earlier demonstrated that cotransporters function as
unconventional water transporters carrying 300–500 water
molecules along with the transported solutes per transport
cycle18,22, rendering the combined solute and water transport
near-isotonic. NKCC1 is prominently featured among these and
has in complementary cell systems been demonstrated to
cotransport water24,26. Here, we reveal that the mouse choroid
plexus displays the ability to transport water against a signiﬁcant
osmotic gradient in a K+-induced, NKCC1-mediated manner.
While the high [K+]o strongly favors inward transport by
NKCC1, and thus robust cell swelling, the high [Na+]o is,
although to a lesser degree, likely to do so as well. However, with
the low apparent afﬁnity of NKCC1 for K+40, the inwardly
directed transport under conditions of high [Na+]o and low [K
+]o and the resulting NKCC1-mediated cell swelling will be
limited and thus likely masked by the parallel osmotically induced
cell shrinkage. Our data align with an earlier study on salamander
choroid plexus, performed with ion-sensitive microelectrodes,
which, however, relied on the KCC for movement of water
independently of the prevalent osmotic gradient25. It should be
emphasized that the NKCC1-mediated component of CSF pro-
duction is a molecular property within the transport protein and
not a result of unstirred layers around the protein or changes in
intracellular osmolarity22.
Our expression studies of mRNA and protein were conducted
on pooled tissue obtained from the lateral and the fourth choroid
plexuses from mouse (to obtain sufﬁcient tissue) and revealed
robust expression of NKCC1. The observation of NKCC1 loca-
lization in the lumen-facing membrane of mouse aligns with
reports on human27 and rat41 choroid plexus. We observed KCC1
expression at the mRNA42,43 and protein level and localized it to
the basolateral membrane, while KCC2-4 mRNA and protein
expression was negligible or below detection limit in our samples.
Lack of KCC2 mRNA and protein in choroid plexus conﬁrms
previous studies42,44, whereas a few reports have assigned KCC3
and KCC4 protein to choroidal tissue28,29 despite absence or
downregulation after birth of mRNA encoding these isoforms
(this study and ref. 43). We speculate that the discrepancy might
arise from insufﬁcient antibody speciﬁcity, by the developmental
changes in KCC mRNA expression43, and/or the distinct
expression proﬁle of the different choroid plexuses45. We are,
nevertheless, left with the conclusion that in adult mouse choroid
plexus, NKCC1 is expressed in the membrane facing the ven-
tricular lumen and KCC1 in the basolateral membrane. The
remarkably high intracellular concentrations of Na+ (~30 mM)
and Cl− (~35 mM) in the mouse choroidal epithelium align with
values obtained in rat1,46 and sufﬁce to promote outwardly
directed NKCC1 transport. This atypical NKCC1 transport
direction was experimentally veriﬁed by complementary techni-
ques, aligns with rat tissue47, and supports the notion that
NKCC1 is uniquely well-suited to participate in CSF production
via its outwardly directed transport in the choroid plexus epi-
thelium (see summary Fig. 7a). This is in contrast to other epi-
thelia and cell types, in which NKCC1 is generally poised towards
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inwardly directed transport48,49. NKCC1 is therefore detected on
the basolateral membrane of other secretory epithelia33.
Optimal CSF production relies on sustained physiological
parameters in the anesthetized animal. We therefore propose that
to reliably measure the rate of CSF production and assign
quantitative contributions of different transport mechanisms, it is
crucial to make every effort to maintain core body temperature
and ensure proper artiﬁcial ventilation of the animal, and hence
physiological values for arterial partial pressure of carbon dioxide
and oxygen, arterial pH, heart rate, and blood pressure. Of note,
ventilated mice had a signiﬁcantly higher CSF production rate of
0.66 ± 0.02 μl min−1 than determined earlier in non-ventilated
mice (0.38 ± 0.02 μl min−1 15) and in our unpublished pilot
experiments. Determination of CSF production by the ventriculo-
cisternal perfusion method relies on dilution of ventricularly
delivered dextran by the newly produced CSF. This method,
however, cannot distinguish between CSF formed by the choroid
plexus (presumably the majority4–7) and that entering the ven-
tricles via the ependymal cell layer following its secretion across
the capillary wall in the reminder of the brain50. The endothelial
expression of NKCC1 is negligible41, and the bumetanide-
sensitive fraction of the CSF production is therefore assigned to
the highly NKCC1-expressing choroid plexus. Inhibition of
NKCC1 (upon intraventricular delivery of inhibitor) decreased
CSF production by 50% in mice, the quantitative importance
underscored by a similar ﬁnding in dogs51. Notably, intravenous
delivery of CCC inhibitors consistently fail to affect CSF pro-
duction rate9,52,53, in alignment with the luminal membrane
expression of NKCC1 illustrated in summary Fig. 7a. The ven-
tricular perfusion rate was set to approximately the same speed as
the CSF production rate, thereby expecting a 1:1 dilution of the
applied inhibitors. While we therefore increased the inhibitor
concentration in the in vivo experimentation compared to that
employed ex vivo, we cannot exclude a lower concentration of
inhibitor reaching the choroid plexus epithelium at the base of the
ventricles, due to the continuous production of CSF and the
ensuing wash out. Taken together with limited reach of the
applied inhibitor to the contralateral ventricle (illustrated with
Evans blue), we predict that our results may underestimate the
quantitative contribution of NKCC1 to CSF production and that
NKCC1 may represent even more than the observed half of the
CSF production machinery.
While in larger animal models, it would be technically feasible
to place cannulas in both lateral ventricles and apply double
lateral perfusion (to determine the full contribution of NKCC1),
it is highly likely that other luminally -expressed membrane
transport mechanisms such as Na+-coupled bicarbonate trans-
porters and the Na+/K+-ATPase also contribute to CSF pro-
duction4,13,14, and may potentially cotransport water. Figure 7b
illustrates a summary of the coupled transporters expressed in the
choroid plexus14,54. The involvement of bicarbonate transporters
has been investigated via inhibition of the carbonic anhydrase by
acetazolamide55,56. As this treatment appears highly vasocon-
strictive especially in choroid plexus57, the ensuing decreased
choroidal blood ﬂow, which in itself lowers CSF production38,
may complicate delineation of the direct role of the bicarbonate
transporters. The slightly increased effect of furosemide over that
of bumetanide in the ventricular-cisternal perfusion experiment,
despite the lack of KCCs in the luminal membrane of the choroid
plexus, may be assigned to the low-afﬁnity inhibitory action of
furosemide on carbonic anhydrase52 and potentially on chloride/
bicarbonate exchange58. The less invasive and rapid whole animal
imaging qualitatively conﬁrmed the role of NKCC1 in CSF
production.
Notably, genetic deletion of NKCC1 is predicted to cause
severe alterations in choroidal epithelium ion concentrations, and
therefore in the driving forces and activity of other choroidal
transport mechanisms (which could add a substantial con-
founding element to data obtained in the NKCC1−/− mouse
model). While NKCC1−/− mice are viable, they, in addition,
display a range of physiological deﬁcits59 and we therefore relied
on the well-tested action of bumetanide. With such a speciﬁc and
effective inhibitor, the advantage of the pharmacological
approach is the acuteness of the transporter inhibition, main-
tenance of normal epithelial ion concentrations, the ability to
employ each mouse as its own control, and the guarantee of no
developmental effects (as observed for the NCBE/NBCn2−/−
mice, in which the luminally localized Na+/H+ exchanger
(NHE1) trafﬁcked to the opposite choroidal membrane60).
In support of the proposed importance of NKCC1 in CSF
production, a recent report convincingly demonstrated hyper-
activation of NKCC1 by inﬂammatory markers in the CSF in an
animal model of intraventricular hemorrhage9. This condition is
well-known to promote posthemorrhagic hydrocephalus in
patients61, and the increased NKCC1 activity in the animal model
yielded bumetanide-sensitive ventriculomegaly. NKCC1, via its
direct contribution to brain water accumulation, thus represents a
promising pharmacological target in brain pathologies involving
disturbed water dynamics and increased intracranial pressure, the
lack of which precludes efﬁcient pharmacological treatment of a
range of patients.
Taken together, our results challenge the general conception
that simple, passive movement of water sufﬁces to support the
high CSF production rate. NKCC1-mediated cotransport of water
ultimately provides a molecular mechanism by which the CSF
production can take place independently of an osmotic gradient
in a manner dictated by the prevailing ion gradients, generated
and maintained by the concerted action of the Na+/K+-ATPase
and the wealth of other ion transporters and channels expressed
in choroid plexus. While the present study addressed the mole-
cular mechanisms of ﬂuid ﬂow from the choroidal epithelial cell
to the ventricle, future studies must delineate the transport
mechanisms underlying ion and ﬂuid ﬂow across the basolateral
membrane. Of immediate interest in this context is the orche-
strated synergy between several bicarbonate transporters14, the
expression of which is illustrated in Fig. 7b.
Methods
Experimental animals. All procedures involving animal experimentation con-
formed to European guidelines, complied with all relevant ethical regulations, and
were approved by the Danish Animal Experiments Inspectorate with permission
no. 2016-15-0201-00944. Adult male B6JBOM (Taconic) or C57BL6J (Janvier
Labs) mice were used for the animal experimentation in ages ranging from 8 to
12 weeks. Housed with 12:12 light cycle and access to water and food ad libitum.
Sample size for the in vivo studies was chosen using the formula62: sample size=
2SD2(1.96+ 0.842)2/d2 with 80% power and type 1 error and using SD (standard
deviation)= 0.06 from ref. 15 and d (effect size)= 0.11 combined from refs. 15,51.
Isolation of choroid plexus from mouse brain. Choroid plexus (CP) was isolated
after cervical dislocation, decapitation and rapid removal and placement of the
brain in cold artiﬁcial CSF solution (aCSF-HEPES) containing (in mM: 120 NaCl,
2.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 10 glucose, 17 Na-HEPES, pH 7.4).
The brains were kept in ice-cold aCSF-HEPES for a minimum of 10 min to cool the
tissue and ease dissection. Choroid plexus was isolated from the lateral and the
fourth ventricles (the latter only employed in expression studies and ex vivo
volume live imaging) after removal of the most lateral 2−3 mm of the brain
hemispheres followed by separation of the two brain hemispheres.
Live imaging. Following isolation, the choroid plexus was stored in ice-cold aCSF-
HEPES up to 3 h prior to experiments and mounted on glass coverslips coated with
Cell-Tak® (BD Biosciences), prepared according to the manufacturer’s instructions
(1 part 2 M Na2CO3:9 parts Cell-Tak, addition of 2% isopropanol to decrease
surface tension, washed twice in aCSF after 30 min drying period). The coverslip
was placed in the closed laminar perfusion chamber (Warner instruments) prior to
loading with 16.67 µM calcein-AM (Life tech), 8–10 min loading followed by a 6–7
min washout period to remove excess dye. Live imaging was performed at 37 °C on
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choroid plexus mounted on an inverted Nikon T2000 microscope stage with a ×60
1.4 NA plan Fluor objective placed underneath the coverslip with immersion oil.
The tissue was superfused with aCSF-HEPES at a ﬂow rate of 1 ml min−1 and swift
solution change was ensured with a PC-16 controller (Bioscience Tools). Hyper-
osmolar solutions were obtained by addition of 100 mOsm mannitol (100 mM),
NaCl (55 mM), or KCl (55 mM). Na+-free aCSF-HEPES (in mM: 120 cholineCl,
2.5 KCl, 2.5 CaCl2, 1.3 MgSO4, KH2PO4, 17 HEPES, 10 glucose (15 mannitol to
obtain ~290 mOsm), pH 7.4). Osmolarities were determined with an accuracy of 1
mOsm with an osmometer Type 15 (Löser Messtechnik). The ﬂuorophore was
excited by light of a wavelength of 495 ± 15 nm delivered by a polychrome IV
monochromator (Photonics). The emitted ﬂuorescence of wave lengths 510–535
nm was recorded for 2–10 ms at a frequency of 1–5 s with a 12-bit cooled
monochrome CCD (Charge-Coupled Device) camera and analyzed with FEI Live
Acquisition software. Each choroid plexus was randomly assigned and all image
analyses were blinded to the experimental conditions. Images of mouse choroid
plexus were converted into black, and background into white using ImageJ per-
centile threshold adjustment. The 2D changes in the black to white ratio were used
to measure relative changes in the size of the choroid plexus. These values represent
an underestimation of the actual 3D volume changes, assuming these are
approximately isotropic but with the relative comparisons employed in this study,
this limitation does not affect the outcome of our data.
mRNA quantiﬁcation. Total RNA from mouse choroid plexus in RNAlater
(R0901, Sigma-Aldrich) was puriﬁed with the RNeasy micro kit (Qiagen) and the
RNase-free DNase set (Qiagen), according to the manufacturer’s instruction. A
total of 0.5 µg total RNA or 1 µg cRNA was used for reverse transcription using the
Omniscript RT mini kit (Qiagen) (cDNA from cRNA was diluted 1:50,000 before
further use). cDNA was ampliﬁed by quantitative PCR conducted using Light-
Cycler 480 SYBR Green I Master Mix (Roche Applied Sciences). Reactions were
carried out in triplicates on a Stratagene Mx3005P QPCR system from Agilent
Technologies. The following primer pairs were applied for ampliﬁcation of targets:
5′-GCAAGACTCCAACTCAGCCAC-3′ (forward) and 5′-ACCTCCATCATC
AAAAAGCCACC-3′ (reverse) to generate an SLC12A2 product of 158 bp; 5′-
GCCCCAACCTTACTGCTGAC-3′ (forward) and 5′-TCTCCTTTAGGCCGA
GGGTG -3′ (reverse) to generate an SLC12A4 product of 150 bp; 5′-TGCTCA
TTGCCGGACTCATT-3′ (forward) and 5′-CCACGTTCTGATCCTGGTCC-3′
(reverse) to generate an SLC12A5 product of 195 bp; 5′-CAGCTGGGGGCTCATA
CTTC-3′ (forward) and 5′-ACTCCGAAAGATGGCAGCTC-3′ (reverse) to gen-
erate an SLC12A6 product of 170 bp; 5′-AGCTCAACGGCGTAGTTCTC-3′ (for-
ward) and 5′-CTGTTCAGCCCTTCCGTCAG-3′ (reverse) to generate an SLC12A7
product of 136 bp; 5′-CCGGGTTCCTATAAATACGGACTG-3′ (forward) and 5′-
CAATCTCCACTTTGCCACTGC-3′ (reverse) to generate a Glyceraldehyd-3-
phosphate (GAPDH) product of 195 bp; 5′-CTCCGGAAAGG
CCAAGACAA-3′ (forward) and 5′-TTTGACGCATTTCCTGCCAAC-3′ (reverse)
to generate an H2A family, member Z (H2AFZ) product of 198 bp.
Primers were designed using NCBI’s pick primer software. The optimum
concentration for each primer set was determined to 200 nM. The initial melting
was performed at 95 °C for 10 min. During the subsequent 40 ampliﬁcation cycles,
the melting temperature was 95 °C (20 s), the primer annealing temperature was
60 °C (22 s), and the elongation temperature was 72 °C (20 s). After completed
ampliﬁcation, melting curves were generated to conﬁrm ampliﬁcation speciﬁcity.
Standard curves of 4× serial dilutions of cDNA were made using either reverse
transcribed cRNA (target genes) or total RNA from mouse choroid plexus
(reference genes) in order to determine the ampliﬁcation efﬁciencies for each of the
utilized primer-sets (SLC12A2 104.3%; SLC12A4 95.1%; SLC12A5 101.2%;
SLC12A6 101.8%; SLC12A7 96.1%, GAPDH 100.5%; and H2AFZ 97.6%). GenEx
(MultiD Analyses AB) was used for data analysis including testing for best
reference gene combinations. Target genes are normalized to GAPDH and
H2AFZT and presented as relative expression.
Protein expression in oocytes and membrane preparations. Oocytes from
Xenopus laevis were obtained from frogs purchased from Nasco (Fort Atkinson) or
purchased from Ecocyte Bioscience (Germany). The oocytes were surgically
removed from anesthetized (2 g l−1 Tricain, 3-aminobenzoic acid ethyl ester,
Sigma-Aldrich A-5040) frogs. The follicular membrane was removed by incubation
in Kulori medium (90 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM
HEPES, pH 7.4, 182 mOsm) containing 10 mgml−1 collagenase (type 1, Wor-
thington, NJ, USA) and trypsin inhibitor (1 mgml−1, Sigma-Aldrich, Denmark)
for 1 h, prior to wash in Kulori medium containing 0.1% bovine serum albumin
(Sigma, Denmark) and incubated in 100 mM K2HPO4 with 0.1% BSA for 1 h. The
oocytes were kept in Kulori medium until experiments. cDNA encoding rNKCC1
was obtained from Professor Kai Kaila (University of Helsinki, Finland) and cDNA
encoding mKCC1-4 was obtained from Professor Hans Gerd NothWang (Carl von
Ossietzky University of Oldenburg, Germany) and all sequences were veriﬁed prior
to use (Euroﬁns Genomics). cRNA was prepared from linearized plasmids using
the mMESSAGE mMACHINE T7 kit (Ambion) and extracted with MEGAclear
(Ambion), according to the manufacturer’s instructions, prior to microinjection of
50 ng cRNA per oocyte with a Nanoject microinjector (Drummond Scientiﬁc
Company). The oocytes were kept at 19 °C for 5 days after which membrane
preparations were obtained by homogenization of 20–40 oocytes expressing each
construct in 1 ml buffer containing (in mM: 5 MgCl2, 5 NaH2PO4, 1 EDTA,
80 sucrose, 20 Tris, pH 7.48, containing the protease inhibitors leupeptin (8 µM)
and pefabloc (0.4 mM), both from Sigma-Aldrich). The supernatant was recovered
following 10 min centrifugation at 250 × g and subsequently centrifuged at
14,000 × g for 20 min to obtain the total membrane fraction.
Western blotting. Isolated choroid plexuses (laterals and fourth) were pooled
from each mouse and sonicated on ice (3 × 10 s at 70%, Sonopuls, Bandelin) in
phosphate-buffered saline (PBS). Western blotting was performed using precast
SDS-PAGE gels (Mini-PROTEAN, Biorad) and immobilon FL-membranes (Merck
Millipore). Both primary and secondary antibodies were diluted in Odyssey
blocking buffer (LI-COR Biosciences):PBS-T at 1:1. Signals were detected with an
Odyssey CLx imaging system and image analysis was performed using Image
Studio 5 (both from LI-COR Biosciences). Full blots with original markers are
included as Supplementary Fig. 1. Primary antibodies: anti-β-tubulin; MAB3408
(Millipore, 1:500), anti-e-cadherin; 610181 (BD BioSciences, 1:5000), anti-NKCC1;
sc-21545 (Santa Cruz, 1:500), anti-KCC1&3 63–66 (kind gift from Professor Tho-
mas J. Jentsch, Max Delbrück Center For Molecular Medicine, Berlin, Germany,
1:500), anti-KCC2; 07-432 (Millipore, 1:1000), anti-KCC3&4 67 (kind gift from
Professor Jinwei Zhang, University of Dundee, UK, 2 µg ml−1), other anti-KCC3
tested; HPA034563 (Atlas, 1:200), H00009990-A01 (Abnova, 1:1000), and sc-19424
(Santa Cruz, 1:200). Secondary antibodies; IRDye 800CW donkey anti-goat; P/N
926-32214, IRDye 680RD donkey anti-mouse; P/N 926-68072, IRDye 800CW
donkey anti-rabbit; P/N 926-32213, and IRDye 800CW goat anti-rabbit; P/N 926-
32211. All from LI-COR Biosciences, 1:10,000-1:15,000.
Cell surface biotinylation. Mice were anesthetized with isoﬂurane, placed in the
prone position in a stereotaxic frame (Harvard Apparatus), a dorsal midline
incision was made over the skull and upper cervical spine to expose the cranium,
after which a brain infusion cannula (Brain infusion kit 3, Alzet) was placed in the
lateral ventricle using the coordinates: 1.0 mm lateral to the midline, 0.5 mm
posterior to bregma, and 2.5 mm ventral into the brain. After sacriﬁcing the mouse
by cervical dislocation, 1.5 mg EZ-link Sulfo-NHS-SS biotin (Thermo Fisher) in
100 μl biotin buffer (in mM: 125 NaCl, 2 CaCl2, 10 triethanolamine, pH 7.5) was
injected to the ventricle and the mouse left on ice for 15 min followed by isolation
of choroid plexus. After isolation and quenching to remove excess biotin, the
choroid plexus was transferred to a lysis buffer (in mM: 150 NaCl, 5 EDTA, 50
Tris-HCl, 1% Triton X-100, 0.05% SDS, 0.4 pefabloc and 8 µM leupeptin) for 30
min, all according to the manufacturer’s instructions. The samples were sonicated
3 × 10 s at 70% (Sonopuls, Bandelin) and centrifuged at 10,000 × g for 5 min at 4 °C.
An aliquot was removed (total fraction) before proceeding with the biotin (lumi-
nal) fraction puriﬁed on NeutrAvidin (Thermo Fisher) columns (Pierce).
Tissue preparation and immunostaining. Sections obtained from tissue from
male C57BL/b mice from Taconic (Denmark) were immunostained with anti-
NKCC1(kind gift from Professor Turner68, 1:4000) and anti-e-cadherin; 610181
(BD Biosciences, 1:2000), prior to labeling with secondary antibody; donkey anti-
mouse; Alexa555 (Invitrogen, 1:1000), donkey anti-rabbit; Alexa488 (Invitrogen,
1:1000) and nuclear staining with Topro3 (Invitrogen, 1:1000). Anti-KCC1 tested;
HPA041138 (Atlas Antibodies), anti-KCC1 (kind gift from Professor Thomas J.
Jentsch), and ab115607 (Abcam). The digital images were acquired with a DM
IRE2 inverted confocal microscope (Leica Microsystems).
Ion content determination. To obtain enough material, samples from four mice
were pooled for each of the four experiments. Mice were anesthetized with xylazine
(only one initial intraperitoneal (i.p.) injection; 1 mgml−1 and 0.1 ml per 10 g body
weight, 37 °C, ScanVet). 5−10 min later, it was followed by an i.p. injection with
ketamine (10 mgml−1 and 0.1 ml per 10 g body weight+ 150 μl for mice <30 g and
200 μl for mice >30 g, 37 °C, MDS Animal Health). With intervals of 25−35 min,
the mouse was re-dosed with ketamine (up to 50% of start dose, as needed to
sustain anesthesia). Anesthetized mice, after tracheotomy, were placed in a ste-
reotaxic frame and clear CSF collected from cisterna magna. Immediately after
decapitation, blood was collected and choroid plexus isolated, weighed, dried at
105 °C, and extracted in 0.1 M HNO3 on a horizontal shaker table (200 rpm, 72 h,
room temperature)69. The ion concentrations of the choroid plexus were calculated
based on previous observations of choroid plexus epithelium containing 79% water
and 8.5% blood69. Na+ and K+ content was quantiﬁed by ﬂame photometry
(Instrument Laboratory 943) while Cl− concentration was quantiﬁed by a colori-
metric method using QuantiChrom™ Chloride Assay Kit (MEDIBENA Life Science
& Diagnostic Solution). Gibbs free energy for NKCC1 was calculated as Eq. 1
ΔG ¼ RT ´ ln ½Na
þi ´ ½Kþi ´ ð½CliÞ2
½Naþo ´ ½Kþo ´ ð½CloÞ2
; ð1Þ
where R= gas constant (8.314 J mol−1), T= temperature (at 37 °C; 310.15 K),
[X]i= intracellular ion concentration, and [X]o= ion concentration in CSF.
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Imaging of intracellular sodium and cell viability. For Na+ imaging of choroid
plexus bathed in aCSF-HEPES, the epithelial cells were loaded (~20 min) with the
membrane-permeable form of SBFI (sodium-binding benzofuran isophthalate
acetoxymethyl (AM) ester, 200 µM, Teﬂabs) To this end, the dye was pressure-
applied (5 s) directly onto the cells on several positions70. Afterwards, the tissue
was perfused with aCSF-HEPES for at least 20 min to allow for de-esteriﬁcation of
the dye before imaging experiments were commenced. Wide-ﬁeld Na+ imaging
was performed utilizing a variable scan digital imaging system (Nikon NIS-
Elements v4.3, Nikon) attached to an upright microscope (Nikon Eclipse FN-PT,
Nikon GmbH). The microscope was equipped with a ×40/N.A. 0.8 LUMPlanFI
water immersion objective (Olympus Deutschland GmbH) and an orca FLASH V2
camera (Hamamatsu Photonics Deutschland GmbH). SBFI was alternatively
excited at 340 and 380 nm. Images were obtained at 1 Hz and emission was col-
lected >440 nm. Fluorescence was evaluated in regions of interest (ROIs), repre-
senting single cells. Signals were background-corrected as follows: The ﬂuorescence
intensities obtained at each excitation wavelength (340/380 nm) were dynamically
subtracted frame by frame by the respective ﬂuorescence emissions of a ROI in the
ﬁeld of view, which was free of SBFI-labeling (background). After background
subtraction, the ﬂuorescence ratio (F340/F380) was calculated from individual ROIs
and analyzed using OriginPro Software (OriginLab Corporation v.9.0). For imaging
of cell survival of the choroid plexus after bumetanide treatment, the epithelial cells
were loaded with Calcein-AM (500 µM, Sigma-Aldrich) as described for SBFI
loading. This was done after 10 min of bumetanide treatment, right before the
blocker washout (or after 10 min of aCSF as a control). Calcein was excited at 488
nm, emission was collected 510 nm. Each choroid plexus was randomly assigned to
each group.
86Rb+ efﬂux experiments. Choroid plexus was isolated as above, initially in cold
aCSF (in mM: 120 NaCl, 2.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 25 NaHCO3,
10 glucose, pH 7.4, equilibrated with 95% O2/5% CO2) but allowed to recover at 37
°C for 5–10 min before beginning of the experiment. Choroidal isotope accumu-
lation was performed by a 10 min incubation in equilibrated (95% O2/5% CO2)
aCSF-based isotope medium (2 μCi ml−1 86Rb+, NEZ07200 (congener for K+
transport) and 8 μCi ml−1 3H-mannitol, NET101 (extracellular marker), both from
PerkinElmer), followed by 15 s wash prior to incubation in 0.5 ml equilibrated
(95% O2/5% CO2) efﬂux medium (aCSF containing 20 μM bumetanide, 1 mM
furosemide or vehicle (DMSO), each choroid plexus randomly assigned to each
group). 0.2 ml of the efﬂux medium was collected into scintillation vials every 20 s
(time points: 0, 20, and 40 s) and replaced with fresh aCSF. At the end of the
experiment, choroid plexus was solubilized at room temperature with 1 ml Solvable
(6NE9100, PerkinElmer) in the leftover efﬂux medium. The isotope content was
determined by liquid scintillation counting with Ultima GoldTM XR scintillation
liquid (6013119, PerkinElmer) in a Tri-Carb 2900TR Liquid Scintillation Analyzer
(Packard). The choroid plexus 86Rb+ content corrected for 3H-mannitol (extra-
cellular background) was calculated for each time point, and the natural logarithm
of the choroid plexus content At/A0 was plotted against time47. Slopes indicating
the 86Rb+ efﬂux rate constants (s−1) were determined from linear regression
analysis.
Ventriculo-cisternal perfusion. Mice were anaesthetized with ketamine and
xylazine (as described above) during the experimental procedure and their body
temperature monitored and maintained at approximately 37 °C using a home-
othermic system (Harvard Apparatus). To obtain near-physiological conditions,
the mice were ventilated (VentElite, Harvard Apparatus) after tracheotomy and
settings continuously optimized for each animal using a capnograph (Type 340,
Harvard Apparatus) and a pulse oximeter (MouseOx®Plus, Starr Life Sciences),
each calibrated with respiratory partial pressure of carbon dioxide and arterial
oxygen saturation (ABL800 FLEX, Radiometer). Ventilation of a ~25 g mouse;
approximately 150 μl per breath of a mix of 0.1 l min−1 O2 and 0.9 l min−1 air and
approximately 150 breath per min, sight= 10 % increase in tidal volume and
Positive End-Expiratory Pressure (PEEP)= 2 cm H2O. The heart rate was con-
tinuously monitored (MouseOx®Plus, Starr Life Sciences). After tracheotomy, 1 ml
of warmed 0.9% NaCl was injected subcutaneously to decrease risk of dehydration.
The infusion cannula was placed as described in the biotinylation method, and was
glued to the scull (with superglue, Pelikan). The perfusion solution was heated to
37 °C in an inline heater (SF-28, Warner Instruments) before entering the infusion
cannula. A micropipette held in a 5° position was introduced into the cisterna
magna. After observing CSF in the micropipette, infusion of equilibrated (95% O2/
5% CO2) aCSF (containing 1−2 mgml−1 tetramethylrhodamine isothiocyanate-
dextran (TRITC-dextran MW 155,000, T1287 Sigma-Aldrich) or 0.03 % w/v Evans
blue (314-13-6 Sigma-Aldrich)) and 0.1% DMSO was initiated at a rate of ~ 0.7 μl
min−1. Addition of dextran and vehicle (DMSO) increased the osmolarity of the
aCSF by approximately 20 mOsm. The ﬁnal osmolarity of the aCSF employed for
the ventricular-cisternal perfusion thus amounted to approximately 313 mOsm,
designed to match the mouse plasma osmolarity (313 ± 2mOsm, n= 5 mice) in
order to limit osmotically induced experimental confounders into the experimental
paradigm. An extra set of mice were anaesthetized with isoﬂurane (0.5–1.5 %) at
the time of CSF production rate determination. Anesthesia was induced as above
(to facility the tracheometry) but the animal transferred to isoﬂurane immediately
thereafter with no subsequent additional ketamine injections. In this manner, the
animal had not been subjected to ketamine/xylazine for at least 2 h and the
dominant anesthesia predicted to be isoﬂurane. After an hour of infusion, the
animals anesthetized with the standard ketamine/xylazine described above were
exposed to a new aCSF solution containing either 2 mM furosemide, 100 μM
bumetanide (expected ventricular concentrations of 1 mM and 50 μM) or the
vehicle, DMSO (animals were randomly assigned to these groups). The solution
change took 5–10 min. Outﬂow was collected in 5-min intervals by introducing a
second micropipette into the ﬁxed cisterna magna micropipette and the ﬂuorescent
content measured in a microplate photometer (Fluoroskan Ascent, Thermo Lab-
systems). The production rate of CSF was calculated from the equation:
Vp ¼ ri ´
Ci  Co
Co
; ð2Þ
where Vp= CSF production rate (µl min−1), ri= infusion rate (µl min-1), Ci=
ﬂuorescence of inﬂow solution, Co= ﬂuorescence of outﬂow solution.
In vivo live imaging. Ventricular injections were done as above, except with var-
iation in the ventricular depth: A cannula was placed 2.5mm into the brain and 2 μl
aCSF with vehicle(DMSO)/inhibitor (2 mM furosemide or 100 μM bumetanide,
animals were randomly assigned to these groups) was injected during 2 s. Within 5
min, the cannula was removed and a new placed 2.2 mm into the brain and the
second solution injected. This second cannula contained aCSF with vehicle/inhi-
bitor, as above, in addition to a carboxylate dye (10 μM IRDye 800CW, P/N 929-
08972, LI-COR Biosciences). With a lapse of 1 min after injection, the ﬁrst image
was obtained on the Pearl Trilogy Small Animal Imaging System (800 nm channel,
85 μm resolution, and 30 s intervals, LI-COR Biosciences). At the termination of
each experiment, a white ﬁeld image was taken. Due to the swift protocol, these
mice were not ventilated. Images were analyzed using Image Studio 5.2 and the
region of interest deﬁned as a square, starting at lambda. For test of whether the
injected solution reached both ventricles, 0.03% w/v Evans blue (314-13-6, Sigma-
Aldrich) dissolved in aCSF was injected in a manner mimicking the injection of
ﬂuorescent dye.
Chemicals. Chemicals were freshly dissolved prior to each experimental day.
Furosemide (F4381, Sigma-Aldrich) was dissolved directly into the aCSF while a
stock solution (100 mM in DMSO) was prepared with bumetanide (B3023, Sigma-
Aldrich).
Statistics. Data analysis and statistical tests were carried out with GraphPrism 7.0
(GraphPad Software). One-sample t test, one-way or two-way (RM)ANOVA fol-
lowed by the Tukey’s multiple comparisons post hoc test were employed as indi-
cated in ﬁgure legends. Data are obtained from choroid plexus from individual
animals and presented as mean ± SEM with signiﬁcance set at P < 0.05.
Data availability. We conﬁrm that all relevant data from this study are available
from the corresponding author upon request.
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